26-Sept-2026 12:25:40

ZYDUS LIFESCIENCES : USFDA INSPECTION OF US OFFICE CONCLUDES WITH NIL OBSERVATIONS

• USFDA conducted an onsite inspection of pharmacovigilance and post marketing surveillance system at the company's office in New Jersey, USA. • The inspection was conducted from September 22nd to September 25th, 2026. • The inspection closed with NIL observations. • This may be considered as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Zydus Lifesciences Limited

← Back to feed